niclosamide has been researched along with Ovarian Neoplasms in 8 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cytotoxicity of niclosamide and its analogs in combination with carboplatin was demonstrated in 24 patient ascites samples." | 3.81 | Niclosamide Analogs for Treatment of Ovarian Cancer. ( Arend, RC; Buchsbaum, DJ; Chettiar, S; Gangrade, A; Hassmann, CJ; Hidalgo, B; Li, PK; Regan, N; Straughn, JM; Walters Haygood, CL, 2015) |
| "Knockdown of FXR1 or IGF2BP2 in ovarian cancer cells resulted in significantly reduced cell viability, adhesion, and migration." | 1.62 | Niclosamide's potential direct targets in ovarian cancer†. ( Bheemireddy, SR; Hayashi, K; MacLean, JA; Matzuk, M; Okuda, H; Plunkett, KN; Pru, C; Sekulovski, N; Yu, Z, 2021) |
| "Niclosamide is an "old" antihelminthic drug that uncouples mitochondria of intestinal parasites." | 1.43 | Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer. ( Bai, MY; Chao, TK; Hu, TM; Huang, RL; Lai, HC; Lin, CK; Su, PH; Wang, YC; Weng, SJ, 2016) |
| "Ovarian cancer is the most lethal gynecologic malignancy, and there is an unmet clinical need to develop new therapies." | 1.43 | A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities. ( Chen, L; Deng, Y; Fan, J; Haydon, RC; He, TC; Hu, X; Liao, J; Liu, H; Luu, HH; Qi, H; Qiao, M; Wang, J; Wang, Z; Wei, Q; Yan, Z; Yu, X; Zhang, F; Zhang, J; Zou, Y, 2016) |
| "Epithelial ovarian cancer (EOC) is the leading cause of gynecologic cancer mortality worldwide." | 1.43 | Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer. ( Alvarez, RD; Arend, RC; Buchsbaum, DJ; Forero, A; Gangrade, A; Hidalgo, B; Katre, AA; Kurpad, C; Landen, CN; Li, PK; Li, Y; Londoño-Joshi, AI; Samant, RS; Straughn, JM; Yang, ES, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (87.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Sekulovski, N | 1 |
| MacLean, JA | 1 |
| Bheemireddy, SR | 1 |
| Yu, Z | 1 |
| Okuda, H | 2 |
| Pru, C | 1 |
| Plunkett, KN | 1 |
| Matzuk, M | 1 |
| Hayashi, K | 2 |
| Arend, RC | 3 |
| Londoño-Joshi, AI | 2 |
| Samant, RS | 2 |
| Li, Y | 2 |
| Conner, M | 1 |
| Hidalgo, B | 3 |
| Alvarez, RD | 2 |
| Landen, CN | 2 |
| Straughn, JM | 3 |
| Buchsbaum, DJ | 3 |
| King, ML | 1 |
| Lindberg, ME | 1 |
| Stodden, GR | 1 |
| Ebers, SD | 1 |
| Johnson, A | 1 |
| Montag, A | 1 |
| Lengyel, E | 1 |
| MacLean Ii, JA | 1 |
| Walters Haygood, CL | 1 |
| Gangrade, A | 2 |
| Chettiar, S | 1 |
| Regan, N | 1 |
| Hassmann, CJ | 1 |
| Li, PK | 2 |
| Lin, CK | 1 |
| Bai, MY | 1 |
| Hu, TM | 1 |
| Wang, YC | 2 |
| Chao, TK | 1 |
| Weng, SJ | 1 |
| Huang, RL | 2 |
| Su, PH | 1 |
| Lai, HC | 2 |
| Deng, Y | 1 |
| Wang, Z | 1 |
| Zhang, F | 1 |
| Qiao, M | 1 |
| Yan, Z | 1 |
| Wei, Q | 1 |
| Wang, J | 1 |
| Liu, H | 1 |
| Fan, J | 1 |
| Zou, Y | 1 |
| Liao, J | 1 |
| Hu, X | 1 |
| Chen, L | 1 |
| Yu, X | 1 |
| Haydon, RC | 1 |
| Luu, HH | 1 |
| Qi, H | 1 |
| He, TC | 1 |
| Zhang, J | 1 |
| Katre, AA | 1 |
| Kurpad, C | 1 |
| Yang, ES | 1 |
| Forero, A | 1 |
| Yo, YT | 1 |
| Lin, YW | 1 |
| Balch, C | 1 |
| Chan, MW | 1 |
| Sytwu, HK | 1 |
| Chen, CK | 1 |
| Chang, CC | 1 |
| Nephew, KP | 1 |
| Huang, T | 1 |
| Yu, MH | 1 |
8 other studies available for niclosamide and Ovarian Neoplasms
| Article | Year |
|---|---|
Niclosamide's potential direct targets in ovarian cancer†.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Humans; Mice; Niclosamide; Ovarian Neoplas | 2021 |
Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
WNT7A/β-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer.
Topics: Animals; beta Catenin; Cell Proliferation; Cells, Cultured; Disease Progression; Drug Resistance, Ne | 2015 |
Niclosamide Analogs for Treatment of Ovarian Cancer.
Topics: Adenocarcinoma, Clear Cell; Aged; Antinematodal Agents; Antineoplastic Agents; Ascites; beta Catenin | 2015 |
Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Biological Availability; Cell Line, Tumor; Cell Proliferation; Drug | 2016 |
A Blockade of IGF Signaling Sensitizes Human Ovarian Cancer Cells to the Anthelmintic Niclosamide-Induced Anti-Proliferative and Anticancer Activities.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiparasitic Agents | 2016 |
Niclosamide and its analogs are potent inhibitors of Wnt/β-catenin, mTOR and STAT3 signaling in ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Checkpoints; Cell Line, Tumor; C | 2016 |
Growth inhibition of ovarian tumor-initiating cells by niclosamide.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Screeni | 2012 |